Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX versus QDOLO.
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist; chlorpheniramine is a histamine H1 receptor antagonist.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
5 mL (hydrocodone 10 mg/chlorpheniramine 8 mg) orally every 12 hours; maximum 10 mL (20 mg hydrocodone/16 mg chlorpheniramine) per 24 hours.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Hydrocodone: 3.8-6 hours (extended-release formulation may have biphasic elimination). Chlorpheniramine: 21-27 hours. Clinical context: Steady-state reached in 2-5 days for chlorpheniramine.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Renal excretion: hydrocodone primarily as conjugates and unchanged drug (~60%), chlorpheniramine primarily as metabolites (~80% renal). Fecal excretion: minimal (<10%).
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist